Clinical bottom line
Advanced liver disease (ALD) presents complex symptom burdens that significantly impair quality of life in palliative care populations. Optimizing symptom management requires a multidisciplinary approach tailored to common gastrointestinal, hepatic, and systemic manifestations such as ascites, pruritus, encephalopathy, and fatigue. Emerging evidence supports early integration of palliative care alongside hepatology to improve symptom control, psychosocial support, and care coordination. However, therapeutic options remain limited by hepatic dysfunction and comorbidities, necessitating cautious individualized treatment plans. Clinicians should prioritize symptom relief while balancing risks of interventions in this vulnerable group.
What the evidence shows
Patients with advanced liver disease frequently experience distressing symptoms including refractory ascites, intractable pruritus, hepatic encephalopathy, nausea, anorexia, and fatigue, which cumulatively degrade quality of life (Chilton et al., 2024). Gastrointestinal symptoms often dominate clinical presentations and require nuanced management strategies (Chilton et al., 2005; 2012). For example, ascites management involves sodium restriction, diuretics, and therapeutic paracentesis, but these interventions must be carefully titrated to avoid renal impairment or electrolyte disturbances (Chilton et al., 2024).
Pruritus, a common and debilitating symptom, may respond variably to bile acid sequestrants, rifampicin, or opioid antagonists, though evidence is largely from observational data and expert consensus (Chilton et al., 2024). Hepatic encephalopathy management centers on lactulose and rifaximin to reduce ammonia levels, but cognitive impairment often persists and complicates care delivery (Patel et al., 2020).
Fatigue and anorexia are prevalent yet under-addressed symptoms; nutritional interventions and psychosocial support are critical but evidence for pharmacologic treatments remains limited (Laddie et al., 2021). Integration of palliative care services early in the disease trajectory has been shown to improve symptom burden, advance care planning, and patient and caregiver satisfaction (Patel et al., 2020; Reed et al., 2018). Symptom prevalence data from palliative care referrals highlight the high unmet needs in this population (Omasta-Martin et al., 2025).
Caveats and uncertainty
Most available evidence derives from observational studies, expert consensus, and small clinical series rather than large randomized controlled trials, limiting the strength of recommendations (Chilton et al., 2024). The heterogeneity of liver disease etiologies and comorbidities complicates extrapolation of findings. Many pharmacologic treatments carry risks of hepatotoxicity or altered metabolism in ALD, requiring vigilant monitoring.
Symptom assessment tools validated specifically for advanced liver disease in palliative settings are scarce, which may lead to under-recognition of symptom severity (Laddie et al., 2021). Furthermore, the impact of cultural, social, and psychological factors on symptom experience and management is incompletely understood.
The timing and extent of palliative care integration remain variable, with some centers lacking protocols for early referral (Reed et al., 2018). More research is needed to define optimal models of care, including telemedicine and multidisciplinary clinics.
How this may change practice
Clinicians caring for patients with advanced liver disease should adopt a proactive, symptom-focused approach emphasizing early palliative care involvement to address complex symptom clusters and psychosocial needs. Regular, comprehensive symptom assessments using validated tools where available can guide individualized management plans.
Therapeutic strategies should balance efficacy with safety, considering altered drug metabolism and potential adverse effects. Non-pharmacologic interventions, including dietary counseling and psychosocial support, are essential adjuncts.
Education of hepatology and palliative care teams on shared care models may improve coordination and patient outcomes. Awareness of the high symptom burden and potential benefits of early palliative care referral can prompt timely discussions about goals of care and advance care planning.
Future developments in symptom-targeted therapies and integrated care pathways hold promise but require validation in robust clinical trials.